← Leaderboards
Judith S Jacobson
Columbia University Health Sciences
$5,594,958
Attributed
$8,536,454
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2005–24$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$8,536,454 · 3
By mechanism
R01$8,536,454 · 3
Top collaborators
- Maureen Joffe11 shared
- Alfred I Neugut11 shared
- Paul Ruff11 shared
- Herbert Cubasch6 shared
- Wafaa M. El-Sadr6 shared
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- Alfred I Neugut$17,537,198
- Olajide Williams$25,189,853
- Mary Beth Terry$27,685,500
- Barun Mathema$2,475,666
- Ramin Mojtabai$6,976,623
Others in their field
Top investigators on “South Africa”
- Myron S Cohen · Family Health International$328,906,964
- Wafaa M. El-Sadr · Columbia University Health Sciences$308,491,923
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$167,971,708
- Carol Nesel · Westat$157,229,158
- Joseph Sparano · Montefiore Medical Center (Bronx, Ny)$129,836,128
- David R. Weir · University Of Michigan At Ann Arbor$111,063,207
Research focus
South AfricaMalignant Breast NeoplasmHospitalsWomanFemaleResearch PersonnelUniversitiesBreast Cancer PatientMalignant NeoplasmsEvidence Based GuidelinesIncidenceCharacteristicsInsightAfrica South Of The SaharaNewly DiagnosedBreast Cancer TreatmentCollaborationsBreastCancer PatientCessation Of LifeBreast Cancer DiagnosisCancer TherapyAntiretroviral TherapyAcademic Medical Centers
Grant awards (15)
Novel predictors of survival among breast cancer patients with/without HIV in South Africa$345,761
R01 · FY2024 · CA
Novel predictors of survival among breast cancer patients with/without HIV in South Africa$347,160
R01 · FY2023 · CA
Novel predictors of survival among breast cancer patients with/without HIV in South Africa$124,999
R01 · FY2023 · CA
Novel predictors of survival among breast cancer patients with/without HIV in South Africa$348,517
R01 · FY2022 · CA
Novel predictors of survival among breast cancer patients with/without HIV in South Africa$474,837
R01 · FY2021 · CA
Novel predictors of survival among breast cancer patients with/without HIV in South Africa$349,996
R01 · FY2020 · CA
HIV's Effects on Breast Cancer Treatment and Outcomes in South Africa$336,973
R01 · FY2019 · CA
HIV's Effects on Breast Cancer Treatment and Outcomes in South Africa$342,373
R01 · FY2018 · CA
HIV's Effects on Breast Cancer Treatment and Outcomes in South Africa$335,700
R01 · FY2017 · CA
HIV's Effects on Breast Cancer Treatment and Outcomes in South Africa$344,783
R01 · FY2016 · CA
HIV's Effects on Breast Cancer Treatment and Outcomes in South Africa$349,644
R01 · FY2015 · CA
Endotoxin, Obesity, and Asthma in NYC Head Start$1,363,596
R01 · FY2005 · HL
Endotoxin, Obesity, and Asthma in NYC Head Start$1,380,222
R01 · FY2004 · HL
Endotoxin, Obesity, and Asthma in NYC Head Start$1,103,284
R01 · FY2003 · HL
Endotoxin, Obesity, and Asthma in NYC Head Start$988,609
R01 · FY2002 · HL